FUNDED RESEARCH
RRP Independent Grant Program
RRP Grants are awarded to investigators who are either developing fundamental reagents/resources for the field or are early in their career and have committed to focusing their attention on RUNX1-FPD.
-
Lucio Castilla, Ph.D.
UMass Chan Medical School
2024 Grant Awardee
"Investigating the Role of TNF Mediated Inflammation in Predisposition to FPD-HM."
-
Ximena Jordan-Bruno, M.D.
University of Pennsylvania
2023 RRP ECI-Clinical Research Grantee
“Establishment of a Biorepository for RUNX1 Patients and Carriers.”
-
Anna Brown, Ph.D.
Centre for Cancer Biology at the University of South Australia and SA Pathology
2018 Grant Awardee
-
Hamish Scott, Ph.D.
Centre for Cancer Biology at the University of South Australia and SA Pathology
2018 Grant Awardee
-
Nancy A. Speck, Ph.D.
University of Pennsylvania
2017 Grant Awardee
“Mouse Models of Secondary Mutations in RUNX1-FPD.”
Publication: Restoring RUNX1 Deficiency in RUNX1 Familial Platelet Disorder by Inhibiting its Degradation
RRP-ALSF Early Career Investigator (ECI) Grant Program
RRP and Alex’s Lemonade Stand Foundation (ALSF) partnered to create the RRP-ALSF Early Career Investigator (ECI) Grant Program, which awards funds for innovative research to discover therapeutics that would prevent high-risk patients from developing leukemia.
-
Dirk Loeffler, Ph.D.
St. Jude Children’s Research Hospital
2023 ECI Grant Awardee
-
Brittany Stewart, Ph.D., C.G.C.
Cleveland Clinic
2023 ECI - Clinical Research Grant Awardee
-
Abbye McEwen, M.D., Ph.D.
University of Washington
2022 ECI Grant Awardee
“Delivering on the promise of germline genetic testing for RUNX1 variant.”
-
Kristy Stengel, Ph.D.
Albert Einstein College of Medicine
2022 ECI Grant Awardee
“Using chemical genetics to define the precise role of RUNX1 in transcription and beyond.”
-
Waihay Wong, M.D., Ph.D.
Brigham & Women’s Hospital
2021 ECI Grant Awardee
“Characterizing inflammatory phenotypes associated with RUNX1 deficiency.”
-
Serine Avagyan, M.D., Ph.D.
University of California San Francisco
2021 ECI Grant Awardee
“Role of PHF6 mutations in germline RUNX1 deficiency associated hematopoietic disorders.”
Publication: B-Cell Acute Lymphoblastic Leukemia in Patients with Germline RUNX1 Mutations
-
Wenbin Xiao, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center
2020 ECI Grant Awardee
“Assessing clonal fitness and mechanisms of clonal evolution in RUNX1-FPD.”
-
Zuzana Tothova, M.D., Ph.D.
Dana-Farber Cancer Institute
2019 ECI Grant Awardee
“Investigating phase-separated condensates in FPD to MDS/AML progression.”
RRP-ALSF Familial RUNX1 Research Grant
RRP and Alex’s Lemonade Stand Foundation (ALSF) partnered to create the RRP-ALSF Familial RUNX1 Research Grant Program, which awards funds for general RUNX1-focused research.
-
Lucio Castilla, Ph.D.
UMass Chan Medical School
2019 Grant Awardee
“Modeling human platelet disorder associated with RUNX1 mutations in mice.”
-
Marc Raaijmakers, M.D.
Erasmus MC Cancer Institute (Rotterdam)
2018 Grant Awardee
“Deconstructing mesenchymal niche contributions to disease pathogenesis in FPD/AML.”
-
Mortimer Poncz, M.D.
Children’s Hospital of Philadelphia
2017 Grant Awardee
“Drug screen for FPD/AML therapeutics.”
Publication: RUNX1 Haploinsufficiency Causes a Marked Deficiency of Megakaryocyte-biased Hematopoietic Progenitor Cells
-
Anupriya Agarwal, Ph.D.
Oregon Health & Science University
2017 Grant Awardee
“Role of inflammatory microenvironment in clonal evolution and progression from FPD to AML.”
-
Ravi Majeti, M.D., Ph.D.
Stanford University
2016 Grant Awardee
“Characterization of pre-leukemia associated with familial RUNX1 mutations.”
-
Alan Cantor, M.D., Ph.D.
Boston Children’s Hospital/Dana-Farber Cancer Institute and Harvard Medical School
2016 Grant Awardee
“Pharmacologic enhancement of residual wild type RUNX1 protein activity in RUNX1-FPD.”
-
Eirini Papapetrou, M.D., Ph.D.
Icahn School of Medicine at Mount Sinai
2016 Grant Awardee
“Identifying therapeutic targets to prevent progression of familial RUNX1 disorder to AML using novel iPSC models.” - PROJECT COMPLETED
Publication: Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells
-
Marshall S. Horwitz, M.D., Ph.D.
University of Washington
2016 Grant Awardee
“Restoring RUNX1 levels in RUNX1-FPD.” - PROJECT COMPLETED
Publication: Restoring RUNX1 Deficiency in RUNX1 Familial Platelet Disorder by Inhibiting its Degradation
-
Leonard I. Zon, M.D.
Boston Children’s Hospital and Harvard Medical School
2016 Grant Awardee
“Modeling RUNX1-associated clonal hematopoietic disorders in zebrafish.” - PROJECT COMPLETED
Publication: Resistance to Inflammation Underlies Enhanced Fitness in Clonal Hematopoiesis
RRP-EVANSMDS Focused Impact REsearch (FIRE) Grant Program
RRP partnered with The Edward P. Evans Foundation, a non-profit Charitable Trust dedicated to funding research on myelodysplastic syndromes (MDS) through its EvansMDS initiative, to award the Focused Impact REsearch (FIRE) Grant.
The grant supports investigations addressing whether modulating inflammatory processes can halt disease progression from clonal hematopoiesis to MDS to AML.
-
Anupriya Agarwal, Ph.D.
Oregon Health & Science University
2021 FIRE Grant Awardee
“Modeling RUNX1-FPD to Identify Interventions Suppressing Myeloid Expansion and Clonal Evolution.”
-
Alexander Bick, M.D., Ph.D.
Vanderbilt University Medical Center
2021 FIRE Grant Awardee
”Identifying Anti-Inflammatory Therapeutics That Prevent Clonal Hematopoiesis Progression in Humans.”
RRP-LLS Grant Program
RRP partnered with the Leukemia & Lymphoma Society (LLS) to provide grants of $200,000 per year for three years for translational leukemia research related to the germline RUNX1 disorder.
-
Guy Sauvageau, M.D., Ph.D.
University of Montreal
2017 Grant Awardee
“RUNX1 Mutations That Confer Exquisite Sensitivity to Glucocorticoids.”
Publication: High Frequency of Germline RUNX1 Mutations in Patients with RUNX1-mutated AML
-
Benjamin L. Ebert, M.D., Ph.D.
Dana Farber Cancer Institute and Harvard Medical School
2017 Grant Awardee
“Interaction of RUNX1 and the Cohesion Complex in Megakaryocyte Development and Myeloid Disease.”
-
Stephen D. Nimer, M.D.
RRP-ALSF Research Accelerating RUNX1 Exploration (RARE) Grant
RRP and Alex’s Lemonade Stand Foundation (ALSF) collaborate to offer this grant supporting research that will accelerate the discovery of druggable oncogenic pathways and deliver cancer interception and cancer prevention therapeutics for RUNX1-FPD children and family members.
-
Robert Bowman, Ph.D.
University of Pennsylvania
2024 RARE Grant Awardee
"Therapeutic targeting of clonal hematopoiesis in RUNX1 mutant FPDMM"
RRP-MFCR Seeking Transformational Research VEnture (STRIVE)
Grant Program
RRP and The Mark Foundation for Cancer Research (MFCR) partnered to offer the STRIVE Grant, which supports innovative studies aimed to delineate the role of inflammation, the immune system and clonal evolution from CHIP to malignancy in RUNX1-FPD. Research should lead to critical insights into cancer initiation and progression.
-
Lucio Castilla, Ph.D.
UMass Chan Medical School
2021 STRIVE Grant Awardee
“Inflammation and Predisposition to Hematologic Malignancies.”
-
Lucy Godley, M.D., Ph.D.
Northwestern University
2021 STRIVE Grant Awardee
“Delineating the Epigenetic Landscape and Pro‐inflammatory Gene Expression Program Associated with Familial Platelet Disorder.”
-
Ravi Majeti, M.D., Ph.D.
Stanford University
2021 STRIVE Grant Awardee
“Characterizing and Targeting Inflammation in RUNX1-Mutant Cancer Progression.”
RUNX1 Team Science Excellence Grant Program (RiSE)
RRP collaborated with the National Institutes of Health (NIH)'s National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), National Human Genome Research Institute (NHGRI) and the National Heart, Lung, and Blood Institute (NHLBI) to offer the RiSE grant, which supports research projects oriented towards the goal of developing novel cancer prevention interventions for RUNX1-FPD patients.
-
Alan Cantor, M.D., Ph.D.
Boston Children’s Hospital/Dana-Farber Cancer Institute and Harvard Medical School
2022 RiSE Grant Awardee
“Rescue of RUNX1 Deficiency Phenotypes in RUNX1-FPD Patients Treated with Imatinib.”
-
Sung-Yun Pai, M.D.
National Cancer Institute
2022 RiSE Grant Awardee
“Rescue of RUNX1 Deficiency Phenotypes in RUNX1-FPD Patients Treated with Imatinib.”
-
Leonard I. Zon, M.D.
Boston Children’s Hospital and Harvard Medical School
2022 Grant Awardee
“Defining Clonal and Metabolic Alterations in the Evolution of RUNX1-FPD.”